Analysts’ Top Healthcare Picks: Genmab (GMAB), Omnicell (OMCL)

TipRanks

Jun. 3, 2025, 03:10 AM

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genmab (GMAB – Research Report), Omnicell (OMCL – Research Report) and Kymera Therapeutics (KYMR – Research Report) with bullish sentiments.

Confident Investing Starts Here:

Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Genmab (GMAB)

William Blair analyst Matt Phipps reiterated a Buy rating on Genmab today. The company’s shares closed last Monday at $21.77.

According to TipRanks.com, Phipps is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.2% and a 38.6% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Ultragenyx Pharmaceutical, and Janux Therapeutics Inc.

Currently, the analyst consensus on Genmab is a Moderate Buy with an average price target of $30.00, which is a 37.7% upside from current levels. In a report issued on May 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Omnicell (OMCL)

Wells Fargo analyst Stan Berenshteyn maintained a Buy rating on Omnicell yesterday and set a price target of $37.00. The company’s shares closed last Monday at $30.20, close to its 52-week low of $25.12.

According to TipRanks.com, Berenshteyn is a 1-star analyst with an average return of -2.8% and a 55.3% success rate. Berenshteyn covers the Healthcare sector, focusing on stocks such as GoodRx Holdings, Health Catalyst, and Veeva Systems.

Omnicell has an analyst consensus of Moderate Buy, with a price target consensus of $40.40, implying a 34.0% upside from current levels. In a report issued on May 22, Benchmark Co. also maintained a Buy rating on the stock with a $40.00 price target.

Kymera Therapeutics (KYMR)

In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Kymera Therapeutics, with a price target of $57.00. The company’s shares closed last Monday at $43.13.

According to TipRanks.com, Archila is a 5-star analyst with an average return of 8.5% and a 48.9% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Arvinas Holding Company, and Monte Rosa Therapeutics.

Currently, the analyst consensus on Kymera Therapeutics is a Strong Buy with an average price target of $53.58, representing a 34.0% upside. In a report issued on May 20, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $55.00 price target.

Read More on GMAB:

Disclaimer & Disclosure Report an Issue